Effectiveness of Ad26.COV2.S Vaccine vs BNT162b2 Vaccine for COVID-19 Hospitalizations
Jérémie Botton, Laura Semenzato, Marie-Joëlle Jabagi, Bérangère Baricault, Alain Weill, Rosemary Dray‐Spira, Mahmoud Zureik
Abstract
This study found that the Ad26.COV2.S vaccine is less effective against COVID-19-related hospitalization than the BNT162b2 vaccine. These results strengthen the evidence supporting a second dose in people who received the Ad26.COV2.S vaccine by an mRNA vaccine as recommended in both France and the US.
Topics & Concepts
Coronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakMedicineVirologyInternal medicineInfectious disease (medical specialty)OutbreakDiseaseSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesVaccine Coverage and Hesitancy